Zhejiang Cheng Yi Pharmaceutical (603811.SH): Injection of choline sodium phosphate passes the generic drug consistency evaluation.

Zhejiang Cheng Yi Pharmaceutical (603811.SH) announced that recently, the company has received the Approval Notice for Drug Supplementary Application issued by the National Medical Products Administration. The company's production of Sodium Choline Phosphoryl Injection has passed the evaluation of generic drug quality and efficacy consistency. Sodium Choline Phosphoryl Injection is mainly used for conscious disorders after acute craniocerebral trauma and brain surgery. As of the disclosure date of the announcement, the company has accumulated approximately RMB 4.2843 million (unaudited) in research and development investment for the consistency evaluation of this drug.